Office to support VEXIM’s product portfolio launch in the U.S.
Toulouse, September 8, 2014 VEXIM (FR0011072602 ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced it has created the VEXIM Inc. legal entity that will serve as the Company’s U.S. subsidiary for marketing VEXIM’s product portfolio in the U.S. It will support VEXIM’s planned commercial launch in early 2015 of vertebroplasty and kyphoplasty solutions to serve the $500M vertebral augmentation market.
VEXIM will approach the U.S. market through a select network of agents and dealers and will be appointing a world-class team of senior sales and marketing professionals to lead and implement this project.
Vincent Gardès, CEO of VEXIM, commented: “We are pleased to have made such substantial progress to be in the position of readying the Company for an opening of our U.S. operations. Our plan is to develop a U.S.-based scientific and business team that can advance the understanding of the benefits of products that better treat vertebral compression fractures. Simultaneously, we are initiating U.S. approval process of SpineJack®, our unique implant designed to repair fractured vertebra and restore anatomical balance to the spinal column, with the goal of bringing SpineJack® to the U.S. as well.”
SpineJack®[2] revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments and guided by X-ray allow the implants into the vertebra to be carried out by mini-invasive surgery in approximately 30 minutes enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.
VEXIM
Vincent Gardès
CEO
Tel: +33 5 61 48 48 38
shareholders@vexim.com
NewCap
Investor Relations / Strategic Communications
Dusan Oresansky /
Emmanuel Huynh
Tel: +33 1 44 71 94 92
vexim@newcap.fr
Alize RP
Press Relations
Caroline Carmagnol/Laure-Line Heim
vexim@alizerp.com
Tel: +33 1 70 22 53 86 /
+33 6 64 18 99 59
LifeSci Advisors LLC
Investor Relations
Michael Wood
www.lifesciadvisors.com
+1 646 597 6983
Help employers find you! Check out all the jobs and post your resume.
